AC Immune的帕金森氏病药 显示出有希望的结果 刺激抗体比安慰剂多16倍 AC Immune's Parkinson's disease drug shows promising results, boosting antibodies 16 times more than placebo.
AC Immune报告说,其第二阶段试验ACI-7104.056(早期帕金森病的免疫疗法)取得了积极的中期结果。 AC Immune has reported positive interim results from its Phase 2 trial of ACI-7104.056, an immunotherapy for early Parkinson's disease. 治疗显示,针对脑中有害蛋白质的抗体大幅增加,没有报告重大安全问题。 The treatment showed significant increases in antibodies targeting harmful proteins in the brain, with no major safety concerns reported. 该药物诱发的抗体比安慰剂多16倍。 The drug induced 16 times more antibodies than the placebo. AC免疫计划进一步进行试验,以评估治疗对症状和生物标志的影响,可能涉及多达150名病人。 AC Immune plans further trials to assess the therapy's impact on symptoms and biomarkers, potentially involving up to 150 patients.